Trial reportBritish journal of clinical pharmacology2012
Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.
Trial report in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 8 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Effectiveness of Classic Triple Therapy Compared with Alternative Regimens for EradicatingMedicina (Kaunas, Lithuania) · 2025Pooled it
- Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.The Korean journal of internal medicine · 2021Guideline
- Evidence-Based Guidelines for the Treatment ofGut and liver · 2021Guideline
- Pooled it
- Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?Journal of Korean medical science · 2014Pooled it
- Guideline
- High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections.Helicobacter · 2014Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- P-CABTherapeutic advances in gastroenterology · 2024Article
- Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment ofTherapeutic advances in gastroenterology · 2023Article
- Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy onGastroenterology and hepatology from bed to bench · 2022Article
- Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-LineGastro hep advances · 2022Article
- High dose PPI-amoxicillin dual therapy for the treatment ofTherapeutic advances in gastroenterology · 2020Review
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
- High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea.Gastroenterology research and practice · 2016Article
- Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.World journal of gastroenterology · 2015Review
- Treatment of Helicobacter pylori infection: current status and future concepts.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection.
methodsTwo hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment.
resultsThe eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002).
conclusionsBecause dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.